Trials that use: Covariate adjustment
5,848 results
- Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): primary endpoint results, effect estimate with confidence…
- Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00555061).
- Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01667796).
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (MT-3724_NHL_003): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003): primary endpoint results, effect…
- Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): primary endpoint results, effect estimate with confidence…
- Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Pharmacological Effects of Crushing Prasugrel in STEMI Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacological Effects of Crushing Prasugrel in STEMI Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02212028).
- PHASEIndependent statistical analysis of Effects of Sulforaphane on Normal Prostate Tissue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00946309).
- Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase 1 Study of PBTZ169: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Study of PBTZ169: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03036163).
- Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00711997).
- Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase 2 Chronic Low Back Pain Study: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Chronic Low Back Pain Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01364922).
- Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4): Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4): primary…
- Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE): Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon): Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: primary endpoint results, effect estimate…
- Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence: Complete Statistical AnalysisIndependent statistical analysis of Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00687713).
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: Complete Statistical AnalysisIndependent statistical analysis of Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo: primary…
- Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL): Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 3 Papulopustular Rosacea Study: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Papulopustular Rosacea Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01493687).
- Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection: Complete Statistical AnalysisIndependent statistical analysis of Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection: primary endpoint results, effect estimate with confidence interval,…
- Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers: primary endpoint…
- Phase I Study of OPC-61815: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of OPC-61815: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03510663).
- Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).